Biogen News and Research

RSS
MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

MS drug TYSABRI to be highlighted at 62nd AAN Annual Meeting

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Crohn's disease: Remicade prescription to decrease, while Humira's increases

Physicians increase prescription of new biologics

Physicians increase prescription of new biologics

Biotech reports record financial results for 2010 first quarter

Biotech reports record financial results for 2010 first quarter

Investment report on Sunesis Pharmaceuticals

Investment report on Sunesis Pharmaceuticals

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Genentech, Biogen Idec file declaratory relief complaint against GSK regarding Arzerra

Biogen Idec and Elan begin comparative trial of MS treatments

Biogen Idec and Elan begin comparative trial of MS treatments

Evotec AG reports financial results and corporate updates for 2009

Evotec AG reports financial results and corporate updates for 2009

EHSI signs profit sharing deal with Celulas Genetica

EHSI signs profit sharing deal with Celulas Genetica

Abbott announces definitive agreement to acquire Facet Biotech

Abbott announces definitive agreement to acquire Facet Biotech

MS Awareness Week: Time for nation to go orange and move it to end MS

MS Awareness Week: Time for nation to go orange and move it to end MS

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

CPEX Pharmaceuticals' fourth-quarter 2009 revenues up 23%

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

Gross sales of Acorda Therapeutics' ZANAFLEX CAPSULES and tablets increase 9.1% to $58.3M in 2009

FDA approves Rituxan-FC combination therapy for CLL

FDA approves Rituxan-FC combination therapy for CLL

Biogen Idec, Swedish Orphan Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc programs

Biogen Idec, Swedish Orphan Biovitrum restructure collaboration agreement for rFVIIIFc and rFIXFc programs

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Combination of daclizumab and interferon beta significantly reduces MS lesion formation

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

Corey McPherson Nash, Biogen Idec team up to create new website for life science community

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Elan announces fourth-quarter and full-year financial results ended December 31, 2009

Biogen Idec reports 2009 fourth quarter and full year earnings

Biogen Idec reports 2009 fourth quarter and full year earnings

Decision Resources: Benlysta to garner more than $500M in 2018

Decision Resources: Benlysta to garner more than $500M in 2018